資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/34345
|
| 標題: | Cost-Effectiveness Evaluation of Add-on Empagliflozin in Patients With Heart Failure and a Reduced Ejection Fraction From the Healthcare System's Perspective in the Asia-Pacific Region |
| 作者: | Liao, Chia-Te
Yang, Chun-Ting
Kuo, Fang-Hsiu
Lee, Mei-Chuan
Chang, Wei-Ting
Tang, Hsin-Ju
Hua, Yi-Ming
Chang, Hung-Yu
Chen, Zhih-Cherng
Strong, Carol
Ou, Huang-Tz
Toh, Han Siong |
| 貢獻者: | Natl Cheng Kung Univ, Dept Publ Hlth, Coll Med
Chi Mei Med Ctr, Div Cardiol, Dept Internal Med
Southern Taiwan Univ Sci & Technol, Dept Elect Engn
Natl Cheng Kung Univ, Inst Clin Pharm & Pharmaceut Sci, Coll Med
Chi Mei Med Ctr, Dept Pharm
Natl Cheng Kung Univ, Inst Clin Med, Coll Med
Southern Taiwan Univ Sci & Technol, Dept Biotechnol
Chang Gung Univ Sci & Technol, Dept Nursing
Natl Yang Ming Chiao Tung Univ, Sch Med, Fac Med
Cheng Hsin Gen Hosp, Ctr Heart
Natl Cheng Kung Univ, Dept Pharm, Coll Med
Chi Mei Med Ctr, Dept Intens Care Med
Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr |
| 關鍵字: | cost-effectiveness
empagliflozin
SGLT2 inhibitor
heart failure with a reduced ejection fraction (HFrEF)
systolic heart failure
Asia-Pacific |
| 日期: | 2021 |
| 上傳時間: | 2023-11-11 11:44:52 (UTC+8) |
| 出版者: | FRONTIERS MEDIA SA |
| 摘要: | Background: EMPEROR-Reduced trial provides promising evidence on the efficacy of empagliflozin adding to the standard treatment in patients with heart failure and reduced ejection fraction (HFrEF). This study aimed to investigate the cost-effectiveness of add-on empagliflozin vs. standard therapy alone in HFrEF from the perspective of the Asia-Pacific healthcare systems. Methods: A Markov model was constructed to simulate HFrEF patients and to project the lifetime direct medical costs and quality-adjusted life years (QALY) of both therapies. Transitional probabilities were derived from the EMPEROR-Reduced trial. Country-specific costs and utilities were extracted from published resources. Incremental cost-effectiveness ratio (ICER) against willingness to pay (WTP) threshold was used to examine the cost-effectiveness. A series of sensitivity analyses was performed to ensure the robustness of the results. Results: The ICERs of add-on empagliflozin vs. standard therapy alone in HFrEF were US$20,508, US$24,046, US$8,846, US$53,791, US$21,543, and US$20,982 per QALY gained in Taiwan, Japan, South Korea, Singapore, Thailand, and Australia, respectively. Across these countries, the probabilities of being cost-effective for using add-on empagliflozin under the WTP threshold of 3-times country-specific gross domestic product per capita were 93.7% in Taiwan, 95.6% in Japan, 96.3% in South Korea, 94.2% Singapore, 51.9% in Thailand, and 95.9% in Australia. The probabilities were reduced when shortening the time horizon, assuming the same cardiovascular mortality for both treatments, and setting lower WTP thresholds. Conclusion: Adding empagliflozin to HFrEF treatment is expected to be a cost-effective option among the Asia-Pacific countries. The cost-effectiveness is influenced by the WTP thresholds of different countries. |
| 關聯: | FRONT CARDIOVASC MED, v.8, pp.750381 |
| 顯示於類別: | [保健營養系(所) ] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| fcvm.2021.750381.pdf | | 696Kb | Adobe PDF | 72 | 檢視/開啟 | | index.html | | 0Kb | HTML | 268 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
